Anemia, characterized by low hemoglobin levels, is a worldwide public health problem with major adverse consequences on human health as well as social and economic development. Although the World Health Organization (WHO) estimates that two billion people - over 30% of the global population - are anemic, there are very few options for point-of-care screening tests available. Young children are at particular risk for anemia which if untreated, can lead to permanent neurologic and cognitive damage. For those with unexpected or acute anemia, screening can enable people to direct self-treatment and, if necessary, direct healthcare providers and systems to allocate medical resources. For those with chronic anemia, timely screening can prevent adverse clinical outcomes and life-threatening complications.
AnemoCheck OTC is a simple, rapid, and accurate point-of-care and over-the-counter self-test for anemia. Each test is patient or parent-operated, self-contained, and disposable. Less than a drop of blood from a finger stick is mixed with our test solution and after 2 minutes the resulting color of the solution correlates to a hemoglobin level. To date, the technology has been FDA cleared for clinical use, and our team is developing an over-the-counter embodiment for use by the general population.
APDC supported development of our AnemoCheck technology which was eventually FDA cleared for clinical use. APDC is currently funding the development of a new form factor, regulatory strategy and risk analysis for an over-the-counter (OTC) version of the AnemoCheck device.